Biomarkers can be tissue based (PD‐L1 expression, Tumor Mutational Burden [TMB], Tumor‐infiltrating lymphocytes [TILs], etc) or serum based (neutrophil‐to‐lymphocyte ratio [NLR], platelet‐to‐lymphocyte ratio [PLR], Blood tumor mutational burden [bTMB], etc).98 The gene discussed is CD274; the disease is neoplasm.